IntelGenx Receives Patent for Oral Film Dosage Form Tech

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced it received a notice of allowance from the United States Patent and Trademark Office for their several of IntelGenx’ oral film products.
As quoted in the press release:

IntelGenx’ new patented oral film technology allows the instant hydration and complete disintegration of a film in the oral cavity, potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption. In addition, the novel oral film dosage form is applicable for reduced absorption through the gastrointestinal route. IntelGenx’ improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability derived from the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix. This oral dosage form technology patent has broad applicability in film formulation and could be applicable to several current and future projects.
“The granting of this notice of allowance for our novel oral film dosage form validates the innovative work carried out by our talented R&D team, which continues to break new ground in the development of oral film technology,” said Horst G. Zerbe, CEO of IntelGenx. “Our rapidly expanding intellectual property portfolio ensures long-term market exclusivity of our products, which is critically important to IntelGenx’ business success. We currently have several additional patent applications pending at the USPTO in relation to oral dosage forms and their method of manufacture, and expect to file for additional patent protection as our research and development continues.”

Click here to read the full press release.
 

Source: www.marketwired.com